Groundbreaking Approval of KOSTAIVE®
KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics, has received significant recognition through its approval by the European Commission. This vaccine distinguishes itself through remarkable immunogenicity and prolonged antibody response lasting up to 12 months post-vaccination, superior to its conventional counterparts.
Impactful Clinical Trials
The approval process follows thorough evaluations led by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The data derived from extensive clinical trials, including an integrated phase 1/2/3 study, showcased KOSTAIVE's impressive efficacy and tolerability. These trials indicated that the vaccine not only provides robust immunity but also ensures longer-lasting efficacy against multiple variants of the SARS-CoV-2 virus, appealingly impacting both younger and older populations.
Importance of mRNA Technology
Self-amplifying mRNA vaccines, like KOSTAIVE, represent a groundbreaking shift in vaccine technology. Unlike conventional mRNA vaccines, this innovative approach enables the body to produce additional mRNA and proteins, enhancing the immune response significantly. CSL and Arcturus are paving the way for future vaccine developments through this technology, which promises greater and more sustained protection against infectious diseases.
Company Commitment and Safety
CSL's dedication to optimizing KOSTAIVE's formulation to suit healthcare professionals' needs reflects its resolve to address ongoing challenges posed by COVID-19. The company's ongoing pursuit of medical advancements is underscored by its commitment to completeness in technical enhancements, aiming to ensure that this pioneering vaccine is available across Europe promptly.
CSL and Arcturus: Leaders in Biotechnology
As a vital player in the biotechnology sector, CSL has an extensive portfolio of life-saving products, including innovations addressing haemophilia, immune deficiencies, and a range of vaccines. CSL's commitment to technology and research excellence fosters the development of groundbreaking medical solutions, positively impacting global health. Likewise, Arcturus Therapeutics has established its reputation for advancing mRNA medicines. The company utilizes its cutting-edge technologies, including LUNAR® lipid-mediated delivery and STARR® mRNA technology, to bring innovative healthcare solutions to the market.
Investor Relations and Future Outlook
With the approval mechanisms in place and a promising clinical background, both CSL and Arcturus prepare to address investor inquiries with calls for collaboration centered around KOSTAIVE's innovative vaccine delivery. As the landscape of infectious disease management evolves, their contributions to mRNA vaccines will play a critical role in shaping public health strategies globally.
Contact Information for Media Inquiries
For additional details regarding KOSTAIVE and its implications for healthcare, CSL provides direct contact with media representatives. Key media contacts include Sue Thorn, with a direct contact number available for rapid inquiries, alongside Em Dekonor from CSL Seqirus addressing specific queries related to vaccine logistics. Furthermore, for those in Australia, CSL’s Jimmy Baker is accessible for local inquiries regarding KOSTAIVE's rollout and implications.
Frequently Asked Questions
What is KOSTAIVE®?
KOSTAIVE® is a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics designed to enhance immune response and offer longer-lasting protection against COVID-19.
How does KOSTAIVE® work?
The vaccine works by utilizing self-amplifying mRNA technology, which instructs the body to produce more mRNA and proteins, ultimately boosting the immune response significantly.
What are the benefits of this vaccine?
KOSTAIVE® has demonstrated improved immunogenicity and antibody persistence for up to 12 months after vaccination, offering potential for broader and more enduring protection.
Where is KOSTAIVE® currently available?
As of now, KOSTAIVE® is marketed in Japan and is seeking broader approval across EU member states, following its recent authorization from the European Commission.
Who to contact for more information?
Media inquiries can be addressed to CSL representatives like Sue Thorn, with provided contact details for extensive discussions about vaccine developments and public health initiatives.
